NasdaqCM - Nasdaq Real Time Price USD
Palvella Therapeutics, Inc. (PVLA)
23.31
-0.50
(-2.10%)
As of 10:02:02 AM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Wesley H. Kaupinen | Founder, President, CEO & Director | 901.07k | -- | -- |
| Ms. Kathleen Goin | Chief Operating Officer | 638.96k | -- | 1971 |
| Dr. Jeffrey Martini Ph.D. | Chief Scientific Officer | 530.43k | -- | 1978 |
| Mr. Matthew E. Korenberg | CFO & Treasurer | -- | -- | 1975 |
| Ms. Bohan Wei | Vice President of Corporate Development & New Product Planning | -- | -- | -- |
| Ms. Emily Cook | Senior Vice President of Clinical Operations | -- | -- | -- |
| Mr. Jason Burdette | SVP of CMC & Technical Operations | -- | -- | -- |
| Ms. Ashley Kline | Chief Commercial Officer | -- | -- | -- |
Palvella Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 14
Description
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
Corporate Governance
Palvella Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
August 12, 2025 at 8:00 PM UTC - August 18, 2025 at 8:00 PM UTC
Palvella Therapeutics, Inc. Earnings Date
Recent Events
Related Tickers
NVCT Nuvectis Pharma, Inc.
8.89
+0.28%
TECX Tectonic Therapeutic, Inc.
22.13
-2.34%
CGEM Cullinan Therapeutics, Inc.
8.71
-3.97%
MNPR Monopar Therapeutics Inc.
38.85
+9.16%
TLSA Tiziana Life Sciences Ltd
1.4509
+1.46%
KLRS Kalaris Therapeutics, Inc.
3.0900
0.00%
CNTA Centessa Pharmaceuticals plc
11.68
-6.78%
IMTX Immatics N.V.
5.71
-0.70%
PRAX Praxis Precision Medicines, Inc.
41.86
+1.19%
FENC Fennec Pharmaceuticals Inc.
7.69
+0.13%